- Home
- REGN vs UBS Comparison
REGN vs UBS Comparison
Compare REGN & UBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REGN
- UBS
- Stock Information
- Founded
- REGN 1988
- UBS 1862
- Country
- REGN United States
- UBS Switzerland
- Employees
- REGN N/A
- UBS N/A
- Industry
- REGN Biotechnology: Pharmaceutical Preparations
- UBS Major Banks
- Sector
- REGN Health Care
- UBS Finance
- Exchange
- REGN Nasdaq
- UBS Nasdaq
- Market Cap
- REGN 110.0B
- UBS 101.8B
- IPO Year
- REGN 1991
- UBS N/A
- Fundamental
- Price
- REGN $738.00
- UBS $31.79
- Analyst Decision
- REGN Buy
- UBS Hold
- Analyst Count
- REGN 24
- UBS 3
- Target Price
- REGN $1,110.63
- UBS $32.18
- AVG Volume (30 Days)
- REGN 887.5K
- UBS 1.5M
- Earning Date
- REGN 10-31-2024
- UBS 10-30-2024
- Dividend Yield
- REGN N/A
- UBS 3.30%
- EPS Growth
- REGN 15.31
- UBS N/A
- EPS
- REGN 40.43
- UBS 1.35
- Revenue
- REGN $13,847,100,000.00
- UBS $47,207,000,000.00
- Revenue This Year
- REGN $10.13
- UBS N/A
- Revenue Next Year
- REGN $4.00
- UBS N/A
- P/E Ratio
- REGN $18.25
- UBS $22.17
- Revenue Growth
- REGN 5.72
- UBS 28.10
- 52 Week Low
- REGN $735.95
- UBS $26.01
- 52 Week High
- REGN $1,211.20
- UBS $33.34
- Technical
- Relative Strength Index (RSI)
- REGN 13.13
- UBS 49.65
- Support Level
- REGN $735.95
- UBS $31.46
- Resistance Level
- REGN $757.56
- UBS $31.91
- Average True Range (ATR)
- REGN 18.56
- UBS 0.38
- MACD
- REGN -1.24
- UBS -0.08
- Stochastic Oscillator
- REGN 1.89
- UBS 25.48
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
About UBS UBS Group AG Registered
The core of UBS is its global wealth management business focusing on high and ultra-high-net-worth individuals. UBS is also a conventional retail and commercial bank in its Swiss home market. Its investment bank and asset management businesses support its wealth management operations, but also leverage its strength in wealth management to serve third-party clients.